Emugrobart's Obesity Failure Exposes Combination Bar; SMA Pivot Rests on Unproven Anti-Myostatin Class

Roche Halts Emugrobart Obesity Development After Phase 2 Disappointment

Roche has discontinued the development of its anti-myostatin therapy, emugrobart, for obesity following a disappointing interim Phase 2 analysis in the GYMINDA trial, where it was tested in combination with tirzepatide. The rights for the asset will revert to its subsidiary, Chugai Pharmaceutical. This decision narrows Roche's near-term strategy in the body composition obesity market, as emugrobart aimed to improve the quality of weight loss by minimizing lean mass loss. Chugai, however, plans to resume development of emugrobart for spinal muscular atrophy (SMA) and is considering advancing it to Phase 3, citing clinical signals and its safety profile. Roche remains committed to obesity care, highlighting its partnership with Hanmi Pharm for HM17321 and assets from the Carmot Therapeutics acquisition, such as enicepatide and petrelintide.

• Roche has decided to discontinue the development of its anti-myostatin therapy, emugrobart, for obesity following a disappointing interim analysis of the Phase 2 GYMINDA trial. The drug, which aimed to preserve lean muscle mass during weight loss by targeting myostatin, was being evaluated in combination with Eli Lilly's tirzepatide. This move, as noted by BMO Capital Markets, significantly narrows Roche's immediate strategy in the competitive body composition obesity market, highlighting the challenges of muscle-sparing approaches.
• The development rights for emugrobart will revert to Roche's majority-owned subsidiary, Chugai Pharmaceutical. Chugai plans to resume the asset's development specifically for spinal muscular atrophy (SMA), citing encouraging "clinical signals," its subcutaneous administration, and a favorable safety profile. Chugai intends to advance emugrobart into Phase 3 for SMA, while also exploring potential out-licensing opportunities, leveraging its managerial independence and in-house product earnings to fund its development.
• Despite the discontinuation of emugrobart, Roche reaffirms its commitment to advancing care for people with obesity and related comorbidities. The company's ongoing obesity pipeline includes assets acquired through the $2.7 billion takeover of Carmot Therapeutics, such as enicepatide, a GLP-1/GIP drug currently in two late-stage studies for weight management. Additionally, Roche is partnered with Zealand Pharma on the amylin drug petrelintide and recently partnered with Hanmi Pharm to advance HM17321, a non-incretin peptide therapy designed to promote weight loss, improve insulin sensitivity, and increase muscle mass.

Roche Halts Emugrobart in Obesity After Mid-Stage Disappointment

Several recent clinical trials have advanced the understanding of pharmacological interventions for obesity. In a randomized, double-blind, placebo-controlled Phase 2b study (NCT04707313), danuglipron (PF-06882961) — an oral small-molecule GLP-1 receptor agonist — was evaluated in 626 adults with obesity over 26 or 32 weeks. All danuglipron dose groups achieved statistically significant weight reductions versus placebo, with least squares mean percentage decreases ranging from -5.0% to -12.9% relative to placebo. The safety profile was consistent with GLP-1 receptor agonist mechanism, with nausea and vomiting as the most frequently reported events; however, discontinuation rates due to adverse events were higher than anticipated across all treatment groups, with approximately 38% of participants discontinuing due to adverse events.

In the STEP TEENS trial (NCT04102189), once-weekly subcutaneous semaglutide 2.4 mg was assessed in adolescents aged 12 to under 18 years with obesity or overweight plus at least one weight-related coexisting condition, over 68 weeks alongside lifestyle intervention. The mean change in BMI from baseline to week 68 was -16.1% with semaglutide versus 0.6% with placebo (estimated difference, -16.7 percentage points; 95% CI, -20.3 to -13.2; P<0.001), and 73% of participants in the semaglutide group achieved weight loss of 5% or more compared with 18% in the placebo group. Improvements in cardiometabolic risk factors — including waist circumference, glycated hemoglobin, and lipid levels — were also greater with semaglutide. The incidence of gastrointestinal adverse events was higher with semaglutide than placebo (62% vs. 42%), and cholelithiasis was reported in 4% of semaglutide-treated participants.

A systematic review and meta-analysis of six randomized controlled trials evaluated tirzepatide — a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist — for weight loss in individuals with overweight or obesity without diabetes mellitus. Tirzepatide demonstrated a mean difference in percentage body weight change of -16.32% (95% CI: -18.35 to -14.29) and an absolute body weight reduction of -13.95 kg (95% CI: -18.83 to -9.07) versus placebo, alongside significant reductions in BMI and waist circumference. Gastrointestinal adverse events were prominent, including elevated relative risks for nausea (RR 3.11), vomiting (RR 5.94), diarrhea (RR 2.92), and constipation (RR 2.85). While overall serious adverse events were not statistically significantly increased (RR 0.93; 95% CI: 0.76–1.13), serious gastrointestinal events and discontinuation due to adverse events were both significantly elevated (RR 3.07 and RR 2.29, respectively).

Navigating the Evolving and Crowded Obesity Treatment Landscape

The past five years have witnessed a marked shift in the obesity treatment landscape, driven by robust clinical trial evidence supporting the efficacy of GLP-1 receptor agonists (GLP-1 RAs) and the emergence of dual-mechanism agents. Subcutaneous semaglutide has established a strong evidence base in adults with overweight or obesity without type 2 diabetes, producing a mean percentage body weight reduction of -11.85% (95% CI: -12.81 to -10.90; P < .00001) versus placebo across four randomized controlled trials involving 3,613 participants. Once-weekly semaglutide has also demonstrated superiority over placebo across categorical weight loss thresholds and cardiometabolic risk factors including waist circumference and BMI. The SELECT trial further elevated semaglutide 2.4 mg (Wegovy®) to a distinct regulatory and clinical position, demonstrating a reduction in three-point major adverse cardiovascular events (3P-MACE) in people with obesity and established cardiovascular disease but without diabetes — establishing it as the first and only anti-obesity medication with proven cardiovascular benefit in this population, including a 2025 approval by India's Central Drugs Standard Control Organization (CDSCO).

Tirzepatide, a once-weekly dual GIP and GLP-1 receptor agonist, has further expanded the therapeutic frontier. A meta-analysis of six randomized trials in individuals with overweight or obesity without diabetes demonstrated a mean percentage body weight reduction of -16.32% (95% CI: -18.35 to -14.29) and an absolute weight reduction of -13.95 kg (95% CI: -18.83 to -9.07) versus placebo, alongside significant reductions in BMI (-5.89 kg/m²) and waist circumference (-12.31 cm). Post hoc analysis of the SURMOUNT-1 trial further characterized the dose-dependent relationship between tirzepatide-induced weight loss and improvements in cardiometabolic parameters — including systolic blood pressure, HOMA-IR, HbA1c, and lipid profiles — with participants achieving at least 35% body weight reduction recording mean systolic blood pressure reductions of up to -14.2 mm Hg and HOMA-IR reductions of -59.7%. The SURPASS-4 and SURMOUNT-1 trials additionally demonstrated tirzepatide's capacity to reduce blood pressure, body weight, and HbA1c in populations with and without T2DM, respectively.

Comparative and indirect evidence is now shaping competitive positioning within this crowded class. A population-adjusted indirect treatment comparison of oral semaglutide 25 mg versus orforglipron 36 mg — using data from OASIS 4 and ATTAIN-1 — showed a significantly greater percentage body weight reduction with oral semaglutide (mean difference: -3.2%-points; 95% CI: -5.9, -0.4; treatment-regimen estimand), alongside substantially lower discontinuation rates due to gastrointestinal adverse events (OR: 13.9; 95% CI: 2.0, 96.0 favouring semaglutide). Head-to-head data from a randomized study in a South Asian cohort further demonstrated that once-weekly semaglutide 2.4 mg produced significantly greater weight loss than once-daily liraglutide 3.0 mg at 68 weeks (-14.7 ± 5.8% vs -6.2 ± 4.9%; p < 0.001). Safety surveillance across the class consistently identifies gastrointestinal adverse events — nausea, vomiting, diarrhea, and constipation — as the predominant tolerability concern, with treatment discontinuation due to adverse events significantly elevated for both semaglutide (RR 2.62; 95% CI: 1.70-4.03) and tirzepatide (RR 2.29; 95% CI: 1.74-3.01) relative to placebo, underscoring the need for individualized dose escalation strategies and ongoing safety surveillance.

Roche's Strategic Pivot: Myostatin's New Path, Incretin's Enduring Reign

The recent decision by Roche to discontinue its anti-myostatin therapy, emugrobart, for obesity following disappointing Phase 2 results marks a significant moment for both the company and the broader pharmaceutical landscape. Emugrobart, an Fc-engineered antibody (GYM329), was designed to inhibit myostatin, a negative regulator of muscle growth, with the aim of preserving lean muscle mass during weight loss—a critical aspect of improving the quality of weight reduction. However, its performance in combination with a highly effective dual GIP/GLP-1 agonist like tirzepatide did not meet expectations, underscoring the formidable efficacy benchmark set by current incretin-based therapies.

This outcome highlights a key challenge in obesity drug development: demonstrating meaningful incremental benefit beyond the already substantial effects of leading agents. While the scientific rationale for myostatin inhibition in preserving muscle mass is compelling, the clinical hurdle for combination therapies in obesity is exceptionally high.

In a strategic pivot, the rights to emugrobart will revert to Chugai Pharmaceutical, which plans to resume its development for spinal muscular atrophy (SMA). This move is logical, as myostatin inhibition directly addresses the core pathology of muscle weakness in SMA, where enhancing muscle strength and mass holds profound clinical significance. Preclinical studies have already demonstrated GYM329's ability to improve muscle strength in disease models, providing a strong foundation for this re-prioritization. However, the clinical efficacy and long-term safety, particularly regarding potential immune effects from its Fc-engineered design, will be crucial considerations as it advances.

Meanwhile, Roche remains committed to the obesity space, shifting its focus to other pipeline assets, including the acquired amylin analogues enicepatide and petrelintide. This aligns Roche with the prevailing trend towards multi-pathway approaches in obesity management. Amylin analogues, often combined with GLP-1R agonists, have shown promising results in clinical trials, offering synergistic effects on satiety, gastric emptying, and weight loss. The competitive landscape for these agents is rapidly intensifying, however, requiring strong differentiation or superior combination strategies to carve out market share. The industry continues to explore novel combinations and mechanisms, but the bar for success, particularly against the backdrop of highly effective incretin and amylin-based therapies, is continually rising.